Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor

Weiguang Sun,Yanli Wu,Mengzhu Zheng,Yueying Yang,Yang Liu,Canrong Wu,Yirong Zhou,Yonghui Zhang,Lixia Chen,Hua Li
DOI: https://doi.org/10.1021/acs.jmedchem.0c00377
IF: 8.039
2020-07-15
Journal of Medicinal Chemistry
Abstract:Tumor necrosis factor α (TNF-α) is an important therapeutic target for rheumatoid arthritis, inflammatory bowel disease, and septic hepatitis. In this study, structure-based virtual ligand screening combined with in vitro and in vivo assays were applied. A lead compound, benpyrine, could directly bind to TNF-α and block TNF-α-trigged signaling activation. Furthermore, the endotoxemic murine model showed that benpyrine could attenuate TNF-α-induced inflammation, thereby reducing liver and lung injury. Meanwhile, administration of benpyrine by gavage significantly relieved the symptoms of collagen-induced arthritis and imiquimod-induced psoriasiform inflammation in mice. Thus, our study discovered a novel, highly specific, and orally active small-molecule TNF-α inhibitor that is potentially useful for treating TNF-α-mediated inflammatory and autoimmune disease.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00377?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00377</a>.Experimental details and spectra of important compounds including the NMR spectra and the HPLC chromatogram as well as the computation results (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00377/suppl_file/jm0c00377_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
chemistry, medicinal
What problem does this paper attempt to address?